PPARA and metabolic dysfunction-associated steatohepatitis: PPAR agonists are known to cause rodent specific HCC [11–13], however in the view of improvement of NASH symptoms by saroglitazar in rodent models and clinical trials it was hypothesized that saroglitazar, PPAR-α/γ dual agonist may prevent development of NASH mediated HCC.